We have recently shown that hydrochlorothiazide use increases the risk of lip and nonmelanoma skin cancer, notably squamous cell carcinoma.
Results | We identified 22 010 cases of melanoma. After exclusions, the final study population comprised 19 273 cases and 192 730 population controls. Cases had slightly lower comorbidity, higher educational level, and higher prevalence of previous nonmelanoma skin cancer than controls. Remaining characteristics were similar between cases and controls.
Overall, 413 cases (2.1%) and 3406 controls (1.8%) were classified as high-users (≥50 000 mg) of hydrochlorothiazide, yielding an adjusted OR of 1 In secondary analyses, we observed associations close to the null for overall melanoma risk with long-term use of bendroflumethiazide (OR, 1.10; 95% CI, 1.02-1.19; P for trend = 0.47), angiotensin-converting enzyme inhibitors (OR, 1.07; 95% CI, 0.99-1.16; P for trend = .53), angiotensin-II receptor antagonists (OR, 1.18; 95% CI, 1.07-1. 29; P for trend = .07), and calcium-channel blockers (OR, 1.06; 95% CI, 0.97-1.14; P for trend = .94). These associations remained neutral in subanalyses stratified by melanoma subtype (data not shown). Comorbidity Index score (0, low; 1-2, medium; or Ն3, high), use of certain drugs (topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines, amiodarone, methoxypsoralen, low-dose aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, statins, or oral steroids), and highest achieved education (short, medium, long, or unknown).
Discussion | The main strength of our study is the use of highquality nationwide registry data. 3 The main limitations are a lack of information on risk factors such as sun exposure, skin pigmentation, and family history of melanoma. However, these characteristics are unlikely to be substantially associated with hydrochlorothiazide use, and thus unlikely to confound out estimates. Thiazide use and melanoma risk has been investigated in a few previous studies; however, only 2 studies, 4,5 both from northern Denmark, have specifically examined hydrochlorothiazide. The first study reported an OR of 1.32 (95% CI, 1.03-1.70) for melanoma risk overall associated with 10 000 mg increments of hydrochlorothiazide. 4 The corresponding OR for hydrochlorothiazide in combination with amiloride was 1.43 (95% CI, 1.09-1.88). 4 The other study found no association between hydrochlorothiazide use combined with amiloride and melanoma risk (OR, 1.02; 95% CI, 0.78-1.33). 5 Neither of these studies included dose-response or histology-specific analyses. The findings for melanoma subtype are somewhat surprising, as lentigo and superficial spreading melanoma are known to be associated with high sun exposure, whereas the etiology of nodular melanomas is less elucidated. 6 It is worrying that hydrochlorothiazide use appears to be associated with an increased risk of melanoma, and the particular associations observed for lentigo melanoma and nodular melanoma warrant further research. 
